High-Dose Cytarabine-Based Regimens vs Liposomal Daunorubicin and Cytarabine in Secondary AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Multicenter Comparison of High-Dose Cytarabine-Based Regimens Versus Liposomal Daunorubicin and Cytarabine (CPX-351) in Patients With Secondary Acute Myeloid Leukemia
Leukemia and Lymphoma 2021 Apr 08;[EPub Ahead of Print], LL Benitez, AJ Perissinotti, CR Rausch, J Klaus, SM Clark, M Filtz, K Ratermann, C Treptow, S Griffin, M Olson, M Crain, T Kadia, K Pettit, PW Burke, DL Bixby, BL MariniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.